Tocilizumab and rituximab reduce relapse rates and disability progression in NMOSD, with tocilizumab provides extra benefits in MOGAD.

In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.

A study suggests a simple treatment algorithm can help reduce racial and ethnic disparities in MS care by increasing the use ...

A new study published in the journal of BMC Nephrology revealed rituximab to be an effective and safe steroid sparing medication in individuals with steroid dependent (SD)/frequent relapsing ...

A simple treatment algorithm to aid in the selection of appropriate DMTs reduces racial disparities in patients with ...

A simple algorithm to recommend disease-modifying therapies may help reduce racial and ethnic inequalities in MS treatment, per a study.

Japanese drugmaker Kyowa Kirin and Swiss generics and biosimilars giant Sandoz have won approval for the partial change of their rituximab biosimilar for the treatment of refractory nephrotic syndrome ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, reviewed how outcomes have changed in patients with primary ...

In standing together, we can ensure that Mercédi’s fight with lupus is not her fight alone. A community mobilised by empathy ...

DelveInsight's "XPOVIO Market Size, Forecast, and Market Insight Report" highlights the details around XPOVIO, a ...

Brukinsa plus R-CHOP demonstrated high efficacy and durable responses in double-expressor lymphoma, with manageable safety, ...

Tailoring rituximab treatment among patients with pemphigus based on the presence of predictors of early relapse reduced relapse rates at 12 months.